Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,274.20569.4
Stock Analysis, IPO, Mutual Funds, Bonds & More
Need ED's satisfaction over dues payments made by Sterling promoters: NCLAT

The tribunal also said the promoters will have to settle their case with the creditors within a specified period.

USFDA issues response letter for new drug application for insulin glargine: Biocon

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.

Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facility

The integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devices was inspected in May 2019.

USFDA issues 12 observations for 3 Biocon units in Malaysia

US health regulator has issued 12 observations after the inspection of three of Biocon's units in Malaysia.

Biocon board approves sale of branded formulations business to subsidiary

The Board of Directors in its meeting approved the sale of Branded Formulations India (BFI) business to Biocon Biologics India (BBIL).

NCLT refers Sterling Biotech for liquidation

“The tribunal has decided to refer the company for insolvency in a verbal order,” said one of the people.

CCI to hold off Monsanto probe for now

The CCI had initiated a probe against the company and the role of its officials and directors following a complaint by several local seed companies led by Nuziveedu Seeds.

NCLT sees violation of Sec 29(A) in Sterling Biotech case

For the second time, the NCLT has questioned the motive of Sterling Biotech's lenders, led by Andhra Bank.

There is compelling need to focus on Biosimilar from govt, patients' point of view: Kiran Mazumdar-Shaw

There is a compelling need to focus on Biosimilar from govt and patients' point of view. Biocon and Mylan are leading the way along with few others in the Biosimilars segment, says Kiran Mazumdar-Shaw of Biocon limited.

How can absconding promoters make one-time-settlement offers, NCLT asks Sterling Biotech lenders

The four promoters of Sterling Biotech are absconding and are facing extradition orders.

Mumbai HC asks Nuziveedu Seeds Ltd  to pay Rs 138 cr dues of Mahyco Monsanto Biotech

Mumbai HC asks Nuziveedu Seeds Ltd to pay Rs 138 cr dues of Mahyco Monsanto Biotech

MMBL sells Bt technology to cotton seed companies under sub-licence agreements.

Supreme Court refuses to stay CCI Monsanto probe

Supreme Court refuses to stay CCI Monsanto probe

CCI has fined both Monsanto Holdings and Mahyco Monsanto Biotech (India).

HC dismisses Monsanto plea against CCI probe of directors

HC dismisses Monsanto plea against CCI probe of directors

A bench of Chief Justice Rajendra Menon and Justice V K Rao said the officers or directors of a company can be proceeded against, along with the entity.

Kiran Mazumdar Shaw bats for easing regulations on biotechnology sector

Kiran Mazumdar Shaw bats for easing regulations on biotechnology sector

"The erstwhile UPA regime and the present Modi government have taken some good steps, but have not done enough to improve the economy," Shaw said.

DowDuPont withdrew GM Corn trials as requisite states didn't give permission

DowDuPont withdrew GM Corn trials as requisite states didn't give permission

Subbarao KV, MD (South Asia), Corteva Agriscience, the agriculture division of DowDuPont, also said that once the Genetic Engineering Appraisal Committee (GEAC) allows commercial cultivation of GM food crop, the company would hold final field trials.

Telangana plans country’s first biopharma hub

Telangana plans country’s first biopharma hub

Telangana government proposes to set up India’s first Biopharma-Hub to provide support to the biopharma research and development activities.

Load More...
1

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service

BACK TO TOP